Compare BlackRock Technology and Private Equity Term Trust (BTX) vs Vertex Pharmaceuticals Incorporated (VRTX) Stock

Vertex Pharmaceuticals Incorporated (VRTX) offers the better valuation at 31.2x trailing P/E (24.7x forward), making it the more compelling value choice. Analysts rate Vertex Pharmaceuticals Incorporated (VRTX) a "Buy" — based on 55 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Vertex Pharmaceuticals Incorporated (VRTX) is the cheapest at 31.2x versus BlackRock Technology and Private Equity Term Trust at 38.9x.

Over the past 5 years, Vertex Pharmaceuticals Incorporated (VRTX) delivered a total return of +125.4%, compared to -45.5% for BlackRock Technology and Private Equity Term Trust (BTX). A $10,000 investment in VRTX five years ago would be worth approximately $23K today (assuming dividends reinvested). Over 10 years, the gap is even starker: VRTX returned +425.4% versus BTX's -45.5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Vertex Pharmaceuticals Incorporated (VRTX) is the lower-risk stock at 0.44β versus BlackRock Technology and Private Equity Term Trust's 1.16β — meaning BTX is approximately 164% more volatile than VRTX relative to the S&P 500.

BlackRock Technology and Private Equity Term Trust (BTX) is the more profitable company, earning 87.7% net margin versus 32.9% for Vertex Pharmaceuticals Incorporated — meaning it keeps 87.7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BTX leads at 87.7% versus 39.1% for VRTX. At the gross margin level — before operating expenses — BTX leads at 100.0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

In this comparison, BTX (12.9% yield) pays a dividend. VRTX does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Vertex Pharmaceuticals Incorporated (VRTX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.44), +425.4% 10Y return). Both have compounded well over 10 years (VRTX: +425.4%, BTX: -45.5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. In terms of investment character: BTX is a small-cap income-oriented stock; VRTX is a mid-cap quality compounder stock. BTX pays a dividend while VRTX does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.